Oxidative stress mediated neuronal damage in the corpus striatum of 6-hydroxydopamine lesioned Parkinson's rats: Neuroprotection by Serotonin, GABA and Bone Marrow Cells Supplementation

Journal of the Neurological Sciences

Volumn 331, Issue 1-2, 2013, Pages 31-37

  Kuruvilla, Korah P ^a   Nandhu, M S ^a   Paul, Jes ^a   Paulose, C S ^a  

^a Department of Physics   (India)

Author keywords

6 hydroxydopamine; Catalase; Glutathione peroxidase; Lipid peroxidation; Oxidative stress; Superoxide dismutase

Indexed keywords

4 AMINOBUTYRIC ACID; ANTIOXIDANT; CATALASE; GLUTATHIONE PEROXIDASE; OXIDOPAMINE; SEROTONIN; SUPEROXIDE DISMUTASE; THIOBARBITURIC ACID REACTIVE SUBSTANCE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIOXIDANT ACTIVITY; APOPTOSIS; ARTICLE; AUTOLOGOUS BONE MARROW TRANSPLANTATION; BONE MARROW CELL; CONTROLLED STUDY; CORPUS STRIATUM; DRUG INFUSION; ENZYME ACTIVITY; GENE EXPRESSION; LIPID PEROXIDATION; MALE; MEDIATOR; NERVE CELL LESION; NEUROPROTECTION; NONHUMAN; OXIDATIVE STRESS; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN ANALYSIS; RAT; REAL TIME POLYMERASE CHAIN REACTION;

EID: 84882448914     PISSN: 0022510X     EISSN: 18785883     Source Type: Journal    
DOI: 10.1016/j.jns.2013.04.020     Document Type: Article

References (63)

1. Mochizuki H, Goto K, Mori H, Mizuno Y. Histochemical detection of apoptosis in Parkinson's disease. J Neurol Sci 1996;137:120-8.
2. Kingsbury AE, Mardsen CD, Foster OJ. DNA fragmentation in human substantia nigra: apoptosis or perimortem effect? Mov Disord 1998;13:877-84.
3. Cohen G, Heikkila RE. The generation of hydrogen peroxide, superoxide radical, and hydroxyl radical by 6-hydroxydopamine, dialuric acid, and related cytotoxic agents. J Biol Chem 1974;249:2447-52.
4. Jenner P. Oxidative stress in Parkinson's disease. Ann Neurol 2003;53(Suppl. 3): S26-38.
5. Permual AS, Tordzro WK, Katz M, Jackson-Lewis V, Cooper TB, Fahn S, et al. Regional effects of 6-hydroxydopamine (6-OHDA) on free radical scavengers in the rat brain. Brain Res 1989;504:139-41.
6. Kumar R, Agarwal ML, Seth PK. Free radical-generated neurotoxicity of 6-hydroxydopamine. J Neurochem 1995;64:1703-7.
7. Choi WS, Yoon SY, Oh TH, Choi EJ, O'Malley KL, Oh YJ. Two distinct mechanisms are involved in 6-hydroxydopamine-and MPP + -induced dopaminergic neuronal cell death: role of caspases, ROS and JNK. J Neurosci Res 1999;57:86-94.
8. Lotharius J, Dugan LL, O'Malley KL. Distinct mechanisms underlie neurotoxinmediated cell death in cultured dopaminergic neurons. J Neurosci 1999;19: 1284-93.
9. Mazzio EA, Reams RR, Soliman KF. The role of oxidative stress, impaired glycolysis and mitochondrial respiratory redox failure in the cytotoxic effects of 6-hydroxydopamine in vitro. Brain Res 2004;1004:29-44.
10. Perumal AS, Gopal VB, Tordzro WK, Cooper TB, Cadet JL. Vitamin E attenuates the toxic effects of 6-hydroxydopamine on free radical scavenging systems in rat brain. Brain Res Bull 1992;29:699-701.
11. Kunikowska G, Jenner P. 6-Hydroxydopamine-lesioning of the nigrostriatal pathway in rats alters basal ganglia mRNA for copper, zinc- and manganese-superoxide dismutase, but not glutathione peroxidase. Brain Res 2001;922:51-64.
12. Oestreicher E, Sengstock GJ, Riederer P, Olanow CW, Dunn AJ, Arendash GW. Degeneration of nigrostriatal dopaminergic neurons increases iron within the substantia nigra: a histochemical and neurochemical study. Brain Res 1994;660: 8-18.
13. Glinka Y, Gassen M, Youdim MB. Mechanism of 6-hydroxydopamine neurotoxicity. J Neural Transm Suppl 1997;50:55-66.
14. Soderstrom KE, Baum G, Kordower JH. Animal models of Parkinson's disease. In: Hof PR, Mobbs CV, editors. Handbook of the neuroscience of aging. Amsterdam: Boston: Elsevier/Academic Press; 2009. p. 551-60.
15. Mayo JC, Sainz RM, Uria H, Antolin I, Esteban MM, Rodriguez C. Melatonin prevents apoptosis induced by 6-hydroxydopamine in neuronal cells: implications for Parkinson's disease. J Pineal Res 1998;24:179-92.
16. Blum D, Torch S, Nissou MF, Benabid AL, Verna JM. Extracellular toxicity of 6-hydroxydopamine on PC12 cells. Neurosci Lett 2000;283:193-6.
17. Asanuma M, Hirata H, Cadet JL. Attenuation of 6-hydroxydopamine-induced dopaminergic nigrostriatal lesions in superoxide dismutase transgenic mice. Neuroscience 1998;85:907-17.
18. Bensadoun JC, Mirochnitchenko O, Inouye M, Aebischer P, Zurn AD. Attenuation of 6-OHDA-induced neurotoxicity in glutathione peroxidase transgenic mice. Eur J Neurosci 1998;10:3231-6.
19. Brazelton TR, Rossi FMV, Keshet GI, Blau HM. From marrow to brain: expression of neuronal phenotypes in adult mice. Science 2000;290:1775-9.
20. Sanchez-Ramos J, Song S, Cardozo-Pelaez F, Hazzi C, Stedeford T, Willing A, et al. Adult bone marrow stromal cells differentiate into neural cells in vitro. Exp Neurol 2000;164:247-56.
21. Woodbury D, Reynolds K, Black IB. Adult bone marrow stromal stem cells express germline, ectodermal, endodermal, and mesodermal genes prior to neurogenesis. J Neurosci Res 2002;96:908-17.
22. Lauder JM, Wallace JA, Krebs H. Roles for serotonin in neuroembryogenesis. Adv Exp Med Biol 1981;133:477-506.
23. Lauder JM. Ontogeny of the serotonergic system in the rat: serotonin as a developmental signal. Ann N Y Acad Sci 1990;600:297-313.
24. Herlenius E, Lagercrantz H. Development of neurotransmitter systems during critical periods. Exp Neurol 2004;190(Suppl. 1):S8-S21.
25. Sudha B, Paulose CS. Induction of DNA synthesis in primary culture of rat hepatocyte by serotonin: possible involvement of serotonin S2 receptor. Hepatology 1998;27: 62-6.
26. BijuMP, Pyroja S, Rajesh KNV, Paulose CS. Enhanced GABA(B) receptor in neoplastic rat liver: induction of DNA synthesis by baclofen in hepatocyte cultures. J Biochem Mol Biol Biophys 2002;6(3):209-14.
27. Paul J, Nandhu MS, Kuruvilla KP, Paulose CS. Dopamine D and D receptor subtypes functional regulation in corpus striatum of unilateral rotenone lesioned Parkinson's rat model: effect of serotonin, dopamine and norepinephrine. Neurol Res 2010;32:918-24.
28. Nandhu MS, Fabia ET, Paulose CS. Dopamine D1 receptor gene expression studies in unilateral 6-hydroxydopamine-lesioned Parkinson's rat: effect of 5-HT, GABA, and bone marrow cell supplementation. J Mol Neurosci 2010;41(1):1-11.
29. Nandhu MS, Paul J, Kuruvila KP, Abraham PM, Antony S, Paulose CS. Glutamate and NMDA receptors activation leads to cerebellar dysfunction and impaired motor coordination in unilateral 6-hydroxydopamine lesioned Parkinson's rat: functional recovery with bone marrow cells, serotonin and GABA. Mol Cell Biochem 2011;353: 47-57.
30. Nandhu MS, Paul J, Kuruvilla KP, Malat A, Romeo C, Paulose CS. Enhanced glutamate, IP3 and cAMP activity in the cerebral cortex of unilateral 6-hydroxydopamine induced Parkinson's rats: effect of 5-HT, GABA and bone marrow cell supplementation. J Biomed Sci 15 2011;18:5.
31. Paul J, Kuruvilla KP, Mathew J, Kumar P, Paulose CS. Dopamine D(1) and D(2) receptor subtypes functional regulation in cerebral cortex of unilateral rotenone lesioned Parkinson's rat model: Effect of serotonin, dopamine and norepinephrine. Parkinsonism Relat Disord 2011;17:255-9.
32. Glowinski J, Iversen LL. Regional studies of catecholamines in the rat brain: The disposition of [3H] norepinephrine, [3H] dopamine and [3H] dopa in various regions of the brain. J Neurochem 1966;13:655-69.
33. Marklund S, Marklund G. Involvement of the superoxide anion radical in the autoxidation of pyrogallol and a convenient assay for superoxide dismutase. Eur J Biochem 1974;47(3):469-74.
34. Aebi H. Catalase in vitro. Methods Enzymol 1984;105:121-6.
35. Flohe L, GunzlerWA. Assays of glutathione peroxidase.Methods Enzymol 1984;105: 114-21.
36. Ohakawa H, Ohnishi N, Yagi K. Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. Anal Biochem 1979;9:351-8.
37. Lowry OH, Roserbbrough NJ, Farr AL, Randall RJ. Protein measurement with Folin phenol reagent. J Biol Chem 1951;193:265-75.
38. Merad-Boudia M, Nicole A, Santiard-Baron D, Saille C, Cebal-los-Picot I. Mitochondrial impairment as an early event in the process of apoptosis induced by glutathione depletion in neuronal cells: relevance to Parkinson's disease. Biochem Pharmacol 1998;56:645-55.
39. Shiraga H, Pfeiffer RF, Ebadi M. The effects of 6-hydroxydopamine and oxidative stress on the level of brain metallothionein. Neurochem Int 1993;23:561-6.
40. Senoh S, Creveling CR, Udenfriend S, Witkop B. Chemical, enzymatic and metabolic studies on the mechanism of oxidation of dopamine. J Am Chem Soc 1959;81: 6236-40.
41. Curtius HC, Wolfensberger M, Steinmann B, Redweik U, Siegfried J. Mass fragmentography of dopamine and 6-hydroxydopamine. Application to the determination of dopamine in human brain biopsies from the caudate nucleus. J Chromatogr 1974;99:529-40.
42. Andrew R, Watson DG, Best SA, Midgley JM, Wenlong H, Petty RK. The determination of hydroxydopamines and other trace amines in the urine of parkinsonian patients and normal controls. Neurochem Res 1993;18:1175-7.
43. Garner CD, Nachtman JP. Manganese catalyzed auto-oxidation of dopamine to 6-hydroxydopamine in vitro. Chem Biol Interact 1989;69:345-51.
44. McGeer PL, Itagaki S, Akiyama H, McGeer EG. Rate of cell death in Parkinsonism indicates active neuropathological process. Ann Neurol 1988;24:574-6.
45. McGeer PL, Itagaki S, Boyes BE, McGeer EG. Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson's and Alzheimer's disease brains. Neurology 1988;38:1285-91.
46. Boka G, Anglade P, Wallach D, Javoy-Agid F, Agid Y, Hirsch EC. Immunocytochemical analysis of tumor necrosis factor and its receptors in Parkinson's disease. Neurosci Lett 1994;172:151-4.
47. Mogi M, Harada M, Riederer P, Narabayashi H, Fujita K, Nagatsu T. Tumor necrosis factor-alpha (TNF-alpha) increases both in the brain and in the cerebrospinal fluid from parkinsonian patients. Neurosci Lett 1994;165:208-10.
48. Hunot S, Brugg B, Ricard D, Michel PP, Muriel MP, Ruberg M, et al. Nuclear translocation of NF-kappaB is increased in dopaminergic neurons of patients with Parkinson disease. Proc Natl Acad Sci USA 1997;94:7531-6.
49. Sofic E, Lange KW, Jellinger K, Riederer P. Reduced and oxidized glutathione in the substantia nigra of patients with Parkinson's disease. Neurosci Lett 1992;142: 128-30.
50. Sian J, Dexter DT, Lees AJ, Daniel S, Agid Y, Javoy-Agid F, et al. Alterations in glutathione levels in Parkinson's disease and other neurodegenerative disorders affecting basal ganglia. Ann Neurol 1994;36:348-55.
51. Riederer P, Sofic E, Rausch WD, Schmidt B, Reynolds GP, Jellinger K, et al. Transition metals, ferritin, glutathione, and ascorbic acid in Parkinsonian brains. J Neurochem 1989;52:515-20.
52. Venkateshappa C, Harish G, Mythri RB, Mahadevan A, Bharath MM, Shankar SK. Increased oxidative damage and decreased antioxidant function in aging human substantia nigra compared to striatum: implications for Parkinson's disease. Neurochem Res 2012;37(2):358-69.
53. Kish SJ, Morito C, Hornykiewicz O. Glutathione peroxidase activity in Parkinson's disease brain. Neurosci Lett 1985;58:343-6.
54. Nikam S, Nikam P, Ahaley SK. Role of free radical and antioxidant imbalance in pathogenesis Parkinson's disease. Biomed Res India 2009;20(1):55-8.
55. Tunçel N, Korkmaz OT, Tekin N, Şener E, Akyüz F, Inal M. Antioxidant and anti-apoptotic activity of vasoactive intestinal peptide (VIP) against 6-hydroxy dopamine toxicity in the rat corpus striatum. J Mol Neurosci 2012;46(1):51-7.
56. Park JW, Youn YC, Kwon OS, Jang YY, Han ES, Lee CS. Protective effect of serotonin on 6-hydroxydopamine- and dopamine-induced oxidative damage of brain mitochondria and synaptosomes and PC12 cells. Neurochem Int 2002;40(3):223-33.
57. Lezoualc'h F, Sparapani M, Behl C. N-acetyl-serotonin (normelatonin) andmelatonin protect neurons against oxidative challenges and suppress the activity of the transcription factor NF-kappaB. J Pineal Res 1998;24(3):168-78.
58. Haydar TF, Wang F, SchwartzML, Rakic P. Differential modulation of proliferation in the neocortical ventricular and subventricular zones. J Neurosci 2000;20:5764-74.
59. Vazquez J, Baghdoyan HA. GABAA receptors inhibit acetylcholine release in cat pontine reticular formation: implications for REM sleep regulation. J Neurophysiol 2004;92(4): 2198-206.
60. Sanchez-Ramos JR, Overvik E, Ames BN. Amarker of oxyradical-mediated DNA damage (8-hydroxy-2'-deoxyguanosine) is increased in nigrostriatum of Parkinson's disease brain. Neurodegeneration 1994;3:197-204.
61. Ebadi M, Srinivasan SK, Baxi MD. Oxidative stress and antioxidant therapy in Parkinson's disease. Prog Neurobiol 1996;48:1-19.
62. Pittenger MF, Mackay AM, Beck SC, Jaiswal RK, Douglas R, Mosca JD, et al. Multilineage potential of adult human mesenchymal stem cells. Science 1999;284: 143-7.
63. Sanchez-Ramos J, Song S, Cardozo-Pelaez F, Hazzi C, Stedeford T, Willing A, et al. Adult bone marrow stromal cells differentiate into neural cells in vitro. Exp Neurol 2000;64:247-56.